Vident Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Vident Advisory’s Portfolio RXRX Stock Details RXRX Fund Activity

Upgrade to unlock

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell
2025 Q1	$53.6K	Sell
2024 Q4	$79.6K	Buy
2024 Q3	–	Sell
2024 Q2	$138K	Sell
2024 Q1	$187K	Sell
2023 Q4	$195K	Sell
2023 Q3	$208K	Buy